Factory Automation Market to Approach USD 370 Billion by 2034, Growing at 6.5% CAGR
Factory Automation (FA) Market Outlook (2025–2034)
Luton, Bedfordshire, United Kingdom, May 28, 2025 (GLOBE NEWSWIRE) -- Market Overview
The global factory automation (FA) market is projected to grow from USD 200 billion in 2024 to nearly USD 370 billion by 2034, expanding at a CAGR of 6.5% over the forecast period. The market is witnessing accelerated growth due to the widespread integration of Industry 4.0 technologies such as the Industrial Internet of Things (IIoT), Artificial Intelligence (AI), and robotics, which are reshaping modern manufacturing ecosystems.
Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/64767/factory-automation-fa-market#request-a-sample
Key Market Insights
Base Year (2024): USD 200 Billion
Forecast Year (2034): USD 370 Billion
CAGR (2025–2034): 6.5%
Historical Period: 2020–2023
Forecast Period: 2025–2034
Largest Regional Market: Asia-Pacific (45% market share)
Market Drivers
1. Adoption of Industry 4.0
The integration of Industry 4.0 principles is one of the most significant drivers of growth in the factory automation market. This industrial revolution is transforming traditional manufacturing into smart, interconnected systems by leveraging technologies such as the Industrial Internet of Things (IIoT), Artificial Intelligence (AI), machine learning, and advanced robotics. These technologies enable real-time monitoring, predictive maintenance, autonomous decision-making, and seamless machine-to-machine communication, significantly improving productivity and process optimization. The rising interest in digital twins and cyber-physical systems is further accelerating the deployment of smart factory solutions across various industries.
2. Operational Efficiency and Productivity Gains
Automation plays a critical role in enhancing operational efficiency, reducing production downtime, and improving overall equipment effectiveness (OEE). Automated systems allow for faster production cycles, higher throughput, and greater accuracy, which is vital for manufacturers dealing with tight deadlines and high variability in demand. In an increasingly volatile global supply chain environment, automation enables rapid adjustments, ensuring continuity and resilience in manufacturing operations.
3. Government Incentives and Policy Support
Governments across the globe are promoting automation through a range of policy initiatives, financial incentives, and subsidy programs. For example, policies like 'Made in China 2025', 'Make in India', Germany's 'Industrie 4.0', and tax incentives in North America are designed to modernize domestic manufacturing capabilities and encourage investment in advanced technologies. These programs often support R&D, workforce training, and infrastructure development, which helps lower the barriers to automation adoption, particularly among small and medium-sized enterprises (SMEs).
4. Rising Demand for Mass Customization
The shift in consumer preferences towards personalized products is fueling the demand for flexible and modular manufacturing systems. Traditional production lines are no longer sufficient to meet the needs of dynamic markets. Instead, manufacturers are investing in automation solutions that allow for rapid reconfiguration, multi-product processing, and on-demand production, thus enabling mass customization at scale. This trend is particularly prominent in industries such as automotive, electronics, and consumer goods, where customer expectations for tailored products are growing rapidly.
Market Challenges
1. High Initial Capital Investment
One of the primary barriers to the adoption of factory automation is the substantial upfront cost associated with acquiring, installing, and integrating automated systems. This includes not only the hardware (robots, sensors, control systems) but also the software, networking infrastructure, and required retrofitting of existing facilities. These capital requirements are particularly challenging for SMEs, which may lack the financial resources or risk tolerance to make such long-term investments without guaranteed returns.
2. Workforce Skill Gaps
The transition to smart manufacturing demands a highly skilled workforce capable of managing complex automation systems, programming industrial robots, analyzing data, and ensuring cybersecurity. However, there is a significant shortage of trained personnel in fields such as automation engineering, mechatronics, and industrial AI. This skills gap slows down the pace of automation adoption and limits the ability of companies to fully exploit the benefits of digital transformation.
3. Regulatory and Compliance Complexities
Navigating the evolving landscape of industrial regulations, safety standards, and environmental compliance poses another challenge for manufacturers. Different countries and regions have varying standards regarding machinery safety (e.g., CE marking in Europe, OSHA in the U.S.), data protection, and energy efficiency, which can complicate system design and deployment. Keeping up with these changes requires additional resources, and non-compliance can result in penalties, delays, or recalls.
4. Supply Chain Disruptions
The global supply chain vulnerabilities witnessed in recent years, due to events such as the COVID-19 pandemic, geopolitical tensions, and semiconductor shortages, have exposed risks in sourcing critical automation components. These disruptions can delay installation schedules, increase costs, and reduce the availability of key equipment like programmable logic controllers (PLCs), sensors, and motors. Integration timelines for new automation projects are often extended as manufacturers struggle to secure essential parts, which in turn affects production scalability and timelines.
Browse full Report - https://exactitudeconsultancy.com/reports/64767/factory-automation-fa-market
Market Segmentation
By Component
Component
Market Share
Key Insight
Sensors
~25%
Integral for real-time data and predictive maintenance.
Actuators
~15%
Essential for precision motion in robotics and control systems.
Robotics
—
Backbone of automated production lines and warehousing.
Industrial Control Systems
—
Foundational for automated decision-making and system monitoring.
HMIs & Safety Components
—
Enable operator interaction and maintain operational safety.
By Technology
Technology
Market Share
Notable Trends
PLCs
~18%
Proven reliability and adaptability across industrial environments.
SCADA
—
Centralized control and monitoring of industrial processes.
IIoT
~20%
Rapid growth driven by smart manufacturing and digital transformation.
DCS, MES
—
Real-time production control and execution optimization.
By Application
Application
Market Share
Description
Process Automation
~30%
Drives consistency and efficiency across batch and continuous operations.
Discrete Automation
~20%
Supports high-volume, varied product manufacturing, especially in electronics.
Others
—
Includes quality control, logistics, and supply chain automation.
By Industry
Industry
Market Share
Key Insights
Automotive
~25%
Transition to electric and autonomous vehicles accelerates automation use.
Food & Beverage
~20%
Ensures compliance, safety, and traceability across production lines.
Electronics, Pharma, Oil & Gas, Chemicals
—
Increasingly reliant on automation for precision and productivity.
By Deployment Type
On-Premises
Cloud-Based – growing due to scalability, remote access, and lower upfront costs.
By End-User
End-User
Market Share
Insight
Small and Medium Enterprises (SMEs)
~30%
Increased adoption driven by falling costs and modular automation solutions.
Large Enterprises
—
Major investors in end-to-end digital transformation initiatives.
Regional Analysis
Asia-Pacific (45% Market Share in 2024)
The Asia-Pacific region continues to lead the global factory automation market, accounting for nearly 45% of the total market share in 2024. This dominance is largely attributed to the region's rapid pace of industrialization, coupled with favorable economic and demographic factors. Countries like China, Japan, South Korea, and India are at the forefront of this growth, each contributing significantly through major investments in manufacturing modernization and industrial digitalization.
China plays a pivotal role, driven by government-led initiatives such as "Made in China 2025," which encourages widespread adoption of intelligent manufacturing and robotics. Japan and South Korea are global leaders in precision manufacturing and robotics, backed by a strong ecosystem of industrial automation technology providers. Meanwhile, India is emerging as a key player due to initiatives like 'Make in India,' increased FDI in manufacturing, and a growing emphasis on industrial upskilling and smart factories.
Additionally, the region benefits from a large labor force, expanding middle-class population, and growing demand for consumer goods, all of which drive the need for automated, efficient, and scalable production systems. Ongoing investments in infrastructure, such as industrial parks and smart cities, further reinforce Asia-Pacific's leading position in the global automation market.
North America (25% Market Share in 2024)
North America holds a substantial share of the factory automation market, estimated at around 25% in 2024. This region is characterized by early and aggressive adoption of advanced automation technologies, including robotics, Industrial IoT (IIoT), AI-driven analytics, and cloud-based automation platforms.
The United States leads the regional market due to its highly developed manufacturing infrastructure, robust research and development ecosystem, and strategic focus on innovation. Automation adoption in North America is driven by labor shortages, rising production costs, and increasing demand for high-quality, customized products. Key sectors utilizing automation include automotive, electronics, pharmaceuticals, and food and beverage industries.
The presence of global technology leaders such as Rockwell Automation, Honeywell, and General Electric further stimulates innovation in the region. Additionally, government support for reshoring manufacturing and investments in digital transformation under initiatives like the CHIPS and Science Act contribute to sustained market growth.
Europe ( 20% Market Share in 2024)
Europe accounts for around 20% of the global factory automation market, supported by its strong tradition of high-quality manufacturing and stringent environmental and safety regulations. The region is known for its early adoption of energy-efficient automation solutions, sustainable manufacturing practices, and highly integrated production environments.
Germany, Italy, and France are the leading contributors in Europe. Germany, in particular, is recognized as a global automation hub due to its leadership in engineering and automotive manufacturing, underpinned by initiatives like 'Industrie 4.0.' Italy and France also play crucial roles with their advanced machinery production and growing adoption of robotics in industrial operations.
European manufacturers emphasize precision, efficiency, and environmental responsibility. As such, automation solutions in this region often integrate features like predictive maintenance, digital twins, and decarbonization tools. Moreover, collaborative efforts between governments, industry associations, and academic institutions support the development and deployment of cutting-edge automation technologies across the region.
Buy Now : https://exactitudeconsultancy.com/purchase/?currency=USD&type=single_user_license&report_id=64767
Emerging Trends and Opportunities
Predictive Maintenance: Widespread adoption driven by IoT-based condition monitoring and machine learning analytics.
Digital Twins: Enabling real-time system simulation, testing, and optimization.
Sustainable Manufacturing: Automation aiding in energy savings, waste reduction, and regulatory compliance.
Flexible Manufacturing Systems (FMS): Rising demand for product personalization driving investments in flexible automation.
Expansion into New Verticals: Pharma, renewable energy, and logistics are increasingly adopting automation to meet precision and scalability needs.
Competitive Landscape
Siemens
Rockwell Automation
Schneider Electric
ABB
Mitsubishi Electric
Honeywell
Emerson Electric
Fanuc Corporation
KUKA
Omron Corporation
Bosch Rexroth
General Electric
Yokogawa Electric Corporation
Beckhoff Automation
Recent Developments:
1. Siemens: Launch of Enhanced TIA Portal for Integrated Automation
In October 2023, Siemens introduced an updated version of its Totally Integrated Automation (TIA) Portal. This advanced software platform is designed to streamline communication between machines, systems, and personnel on production floors. The latest iteration incorporates AI-driven predictive maintenance and improved interoperability, enabling manufacturers to optimize production efficiency and reduce downtime. This development aligns with the industry's shift towards Industry 4.0, offering a competitive edge to early adopters seeking to modernize their facilities.
2. Rockwell Automation and Microsoft: Integration of Generative AI in Automation Design
In October 2023, Rockwell Automation and Microsoft expanded their longstanding partnership to accelerate industrial automation design and development through generative artificial intelligence (AI). The collaboration integrates Microsoft's Azure OpenAI Service into Rockwell's FactoryTalk® Design Studio™, enabling engineers to generate code using natural language prompts. This innovation aims to automate routine tasks, improve design efficiency, and expedite time-to-market for customers building industrial automation systems. The partnership addresses challenges such as skilled labor shortages and is poised to set new standards in automation technologies.
3. ABB: Acquisition of Real Tech for Enhanced Water Monitoring Solutions
In January 2024, ABB acquired Real Tech, a Canadian company specializing in innovative optical sensor technology for real-time water monitoring and testing. This strategic acquisition enhances ABB's portfolio in smart water management solutions, allowing for more precise and efficient monitoring of water quality. The integration of Real Tech's technology is expected to provide customers with advanced tools for environmental monitoring, reflecting ABB's commitment to sustainability and innovation in industrial automation.
4. Honeywell: Development of Honeywell Forge for Industrial Analytics
In June 2023, Honeywell announced the development of Honeywell Forge for Industrial, an advanced analytics software designed to optimize performance across various industrial sectors. This software incorporates AI and machine learning, allowing companies to monitor critical equipment in real time and reduce operational disruptions. The technological advancement aligns with industry trends towards predictive maintenance and enhanced operational efficiency, setting a new benchmark in analytics capabilities.
5. Mitsubishi Electric: Expansion of Manufacturing Facilities in India
In December 2023, Mitsubishi Electric India inaugurated a new manufacturing facility for advanced factory automation systems in the Talegaon Industrial area, Maharashtra. The facility, backed by a greenfield investment of ₹220 crore, spans 40,000 square meters and is designed to meet the growing demand for advanced automation and smart manufacturing solutions in India. The plant aims to enhance local manufacturing capabilities, reduce delivery times, and support the 'Make in India' initiative by providing energy-saving equipment and solutions that utilize automation technology.
This report is also available in the following languages : Japanese (ファクトリーオートメーション（FA）市場), Korean (공장 자동화(FA) 시장), Chinese (工厂自动化（FA）市场), French (Marché de l'automatisation industrielle (FA)), German (Markt für Fabrikautomatisierung (FA)), and Italian (Mercato dell'automazione di fabbrica (FA)), etc.
Get a Sample PDF Brochure: https://exactitudeconsultancy.com/reports/64767/factory-automation-fa-market#request-a-sample
More Research Finding –Ethernet PHY Chips MarketThe Ethernet PHY chips market is projected to be valued at approximately $3.5 billion in 2024, with significant growth anticipated during the forecast period from 2025 to 2034, potentially reaching around $6.8 billion. This indicates a robust Compound Annual Growth Rate (CAGR) of roughly 7% over the next decade, driven by increasing demand for faster, more reliable networking solutions.https://exactitudeconsultancy.com/reports/64838/ethernet-phy-chips-market
Surface Mount Solid State Relays MarketThe global market for Surface Mount Solid State Relays (SSR) is valued at approximately $1.2 billion, driven by increasing demand in industries such as automotive, telecommunications, and automation. The market is expected to grow significantly, with projections estimating it will reach around $2.3 billion by 2034, reflecting robust adoption across various applications such as lighting controls and HVAC systems.https://exactitudeconsultancy.com/reports/64830/surface-mount-solid-state-relays-market
Air Cargo & Freight Logistics MarketThe global air cargo and freight logistics market is valued at approximately $150 billion, driven by increasing e-commerce demands and globalization of supply chains. The market is projected to reach around $250 billion by 2034, reflecting a robust growth trajectory. The Compound Annual Growth Rate (CAGR) for the forecast period from 2025 to 2034 is estimated at 5.3%, spurred by advancements in technology and automation in logistics operations.https://exactitudeconsultancy.com/reports/64785/air-cargo-freight-logistics-market
System on Module SOM MarketThe Global System on Module (SOM) market is valued at approximately $1.75 billion in 2024, with projections indicating a robust growth trajectory, aiming to reach around $4.5 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of about 9.5% during the forecast period from 2025 to 2034.https://exactitudeconsultancy.com/reports/64588/global-system-on-module-som-market
Biped Robot MarketThe global biped robot market is poised for significant growth, currently valued at approximately $6.3 billion in 2024. The market is projected to reach around $15.2 billion by 2034, growing at a robust Compound Annual Growth Rate (CAGR) of about 9.1% from 2025 to 2034. This growth trajectory is driven by advancements in robotics technologies, increasing demand for automation in various sectors, and rising investments in research and development.https://exactitudeconsultancy.com/reports/64556/global-biped-robot-market
OHT for Semiconductor Manufacturing Lines MarketThe global Overhead Transport (OHT) market for semiconductor manufacturing lines is valued at approximately $2.3 billion in 2024. It is expected to reach $4.9 billion by 2034, indicating significant growth driven by the increasing demand for advanced semiconductor technologies and miniaturization in electronic devices. The projected Compound Annual Growth Rate (CAGR) for this period is approximately 8.1%.https://exactitudeconsultancy.com/reports/64552/global-oht-for-semiconductor-manufacturing-lines-market
Parcel Separator MarketThe global parcel separator market is valued at approximately $1.35 billion in 2024 and is projected to reach around $2.6 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 7.1% during the forecast period from 2025 to 2034.https://exactitudeconsultancy.com/reports/64540/global-parcel-separator-market
Servo System Controller MarketThe global servo system controller market is projected to reach approximately $8.5 billion in 2024, driven by increasing automation in manufacturing processes and advancements in robotics technology. As industries seek to enhance precision and efficiency, the demand for sophisticated servo controllers is expected to intensify. The market is forecasted to expand significantly, with an estimated value of around $13.2 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of about 4.8% during the period from 2025 to 2034.https://exactitudeconsultancy.com/reports/64492/global-servo-system-controller-market
Magnetic Angle Encoder IC MarketThe global magnetic angle encoder integrated circuit (IC) market is poised for significant growth, with an estimated market value of approximately $1.2 billion in 2024. This market is projected to reach around $2.3 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of about 7.2% during the forecast period from 2025 to 2034.https://exactitudeconsultancy.com/reports/64469/global-magnetic-angle-encoder-ic-market
Magnetic Encoder Chip MarketThe global magnetic encoder chip market is valued at approximately $2.1 billion in 2024 and is projected to reach around $3.5 billion by 2034, reflecting a robust growth trajectory. This translates to a Compound Annual Growth Rate (CAGR) of about 5.2% during the forecast period from 2025 to 2034.https://exactitudeconsultancy.com/reports/64468/global-magnetic-encoder-chip-market
Piezoelectric Actuators MarketThe global piezoelectric actuators market is projected to reach a value of approximately $3.6 billion in 2024, driven by the increasing demand across industries such as automotive, healthcare, and aerospace. The market is expected to grow significantly, with a compounded annual growth rate (CAGR) of around 7.2% during the forecast period from 2025 to 2034, potentially reaching $7.4 billion by 2034.https://exactitudeconsultancy.com/reports/64271/global-piezoelectric-actuators-market
3C Smart Peripheral Products MarketThe global 3C smart peripheral products market is valued at approximately $150 billion in 2024, with projections indicating significant growth, reaching around $250 billion by 2034. This represents a Compound Annual Growth Rate (CAGR) of around 5.2% over the forecast period from 2025 to 2034, driven by increased consumer demand for interconnected devices and smart technology integration.https://exactitudeconsultancy.com/reports/64261/global-3c-smart-peripheral-products-market
Photoelectric Sensors MarketThe global photoelectric sensors market is valued at approximately $3.5 billion in 2024 and is projected to reach around $5.8 billion by 2034, reflecting a robust Compound Annual Growth Rate (CAGR) of about 5.2% during the forecast period from 2025 to 2034.https://exactitudeconsultancy.com/reports/64239/global-photoelectric-sensors-market
Surface Inspection Equipment MarketThe global surface inspection equipment market is valued at approximately $4.5 billion in 2024, with an anticipated growth trajectory leading to a projected market value of around $8.2 billion by 2034. This forecast indicates a Compound Annual Growth Rate (CAGR) of approximately 6.5% from 2025 to 2034.https://exactitudeconsultancy.com/reports/64216/global-surface-inspection-equipment-market
Integration Platform as a Service iPaaS Future TrendsThe Global Integration Platform as a Service (iPaaS) market is valued at approximately $8.2 billion, driven by the increasing need for organizational agility and operational efficiency. The market is forecasted to reach around $20.5 billion by 2034, indicating substantial growth opportunities.https://exactitudeconsultancy.com/reports/64147/global-integration-platform-as-a-service-ipaas-market
Low-Voltage Differential Signaling LVDS Chip Future TrendsThe global Low-Voltage Differential Signaling (LVDS) chip market is valued at approximately $3.1 billion in 2024, with expectations to reach around $5.6 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of approximately 6.4% during the forecast period of 2025-2034.https://exactitudeconsultancy.com/reports/64070/global-low-voltage-differential-signaling-lvds-chip-market
PID Temperature Regulators MarketThe global PID temperature regulators market is poised to reach an estimated value of $2.5 billion in 2024, driven by increasing demand across industries such as manufacturing, HVAC, and food processing. The market is projected to grow at a robust Compound Annual Growth Rate (CAGR) of 8.5% from 2025 to 2034, reaching approximately $5 billion by the end of the forecast period.https://exactitudeconsultancy.com/reports/64027/global-pid-temperature-regulators-market
Software Testing MarketThe global software testing market is poised for significant growth, valued at approximately $50 billion in 2024. Projections indicate that the market will reach about $110 billion by 2034, reflecting the critical importance of quality assurance in increasingly complex software environments. The anticipated Compound Annual Growth Rate (CAGR) for the period from 2025 to 2034 is estimated to be around 8.1%, driven by the ongoing digital transformation across industries.https://exactitudeconsultancy.com/reports/64009/global-software-testing-market
Special Equipment Manufacturing MarketThe global special equipment manufacturing market is projected to reach approximately USD 250 billion in 2024. This sector encompasses a diverse array of industries, including construction, mining, and specialized machinery. The market is expected to exhibit robust growth, reaching an estimated value of USD 425 billion by 2034, reflecting a Compound Annual Growth Rate (CAGR) of 5.3% from 2025 to 2034.https://exactitudeconsultancy.com/reports/63940/global-special-equipment-manufacturing-market
CONTACT: Contact Data Irfan Tamboli (Head of Sales) Phone: + 1704 266 3234 Email: sales@exactitudeconsultancy.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Data Speaks Officially Launches to Redefine Marketing Measurement for the Digital Era
Portland-based firm introduces transparent, AI-powered platform to help marketers identify true sales drivers and stop wasting budget PORTLAND, OR, May 30, 2025 (GLOBE NEWSWIRE) -- After a year of rigorous testing in private beta, officially launches to the public on May 15, bringing a new level of transparency and accuracy to the world of marketing attribution. Designed for modern brands navigating increasingly complex digital ecosystems, Data Speaks offers a unified, AI-powered platform that finally answers the question: 'What's really driving your sales?'Media mix modeling and incrementality testing platform Founded by a team of data scientists from Stanford and MIT alongside veteran marketers, Data Speaks is built to eliminate the guesswork surrounding campaign performance. Unlike platform-specific tools that provide a limited view, the platform unifies marketing data across every major channel like Meta, Google Ads, TikTok, Amazon, Shopify, and more to deliver a full-picture analysis of actual incremental marketers face a paradox. While data is more abundant than ever, it's also harder to trust. Legacy attribution models, often reliant on third-party cookies and click-based logic, fall short in capturing the true impact of omnichannel campaigns. This leads to a fragmented view of performance and misplaced budget decisions. 'Marketers are not short on data; they're short on clarity,' said Zeke Camusio, CEO and Founder of Data Speaks. 'We built this platform to change that. Our goal is to provide the kind of transparency and insight that empowers brands to invest with confidence, knowing exactly what's working and what's not.' Backed by advanced media mix modeling, incrementality experiments, first-party tracking, and AI analytics, the platform aims to deliver enterprise-level intelligence at a scale and cost accessible to growth-stage DTC brands and performance-driven agencies. What the Launch Includes The official public release of comes with a suite of robust capabilities designed to close attribution gaps and improve decision-making: Attribution Modeling: Understand how each touchpoint contributes to revenue. Incrementality Testing: Separate correlation from causation to determine actual lift. Privacy-Friendly First-Party Tracking: A future-proof solution that complies with evolving browser policies and user privacy standards. Ecommerce Analytics: Connect marketing outcomes to real business metrics across digital and retail. Strategic Consulting: Optional advisory services for teams seeking expert interpretation and support. These tools are aimed at helping brands stop relying on black-box attribution and start embracing evidence-based growth strategies. Why It Matters Now Recent industry data highlights the urgency for more accurate ecommerce attribution: 42% of conversions go untracked due to ad blockers and privacy settings. 38% fall outside limited attribution windows. 53% of conversions are claimed by multiple channels simultaneously. Only 61% of platform-attributed conversions are actually incremental. The result? Marketing teams are left guessing. This gap not only wastes budget but also obscures opportunities for scale. With Data Speaks, brands report a 35% improvement in ROAS, 10X better attribution accuracy, and 72% more conversions tracked, offering a compelling case for rethinking how performance is measured. Designed for the Marketer, Not the Algorithm While many analytics tools cater to data engineers, Data Speaks prioritizes usability for marketers. Its interface is intuitive, insights are visualized clearly, and reports are built to drive real-world actions. Whether managing a single brand or multiple clients, users can compare campaigns, forecast impact, and reallocate spend with clarity. The platform's flexibility also ensures it adapts to changing market dynamics and emerging channels, making it an ideal long-term partner for modern marketing teams. Built for the Future of Attribution In a landscape where digital marketing is evolving rapidly, staying ahead means moving beyond legacy systems. Data Speaks represents a shift toward measurable, meaningful outcomes supported by unbiased modeling and transparent data science. 'Brands deserve better than guesswork,' Camusio added. 'They deserve answers grounded in evidence, not assumptions. With Data Speaks, we're helping them reclaim control of their marketing strategy.' As adoption of AI analytics and first-party tracking accelerates, Data Speaks is positioned to be the go-to solution for brands that demand clarity in their performance metrics. About Data Speaks Data Speaks is a marketing measurement platform that helps brands uncover what truly drives their sales. Founded by data scientists and seasoned marketers, the platform combines media mix modeling, incrementality testing, and AI analytics to offer an accurate, transparent view of marketing performance across every channel. Based in Portland, Oregon, Data Speaks supports ecommerce brands, agencies, and growth-stage businesses looking for smarter, more reliable insights without the complexity of enterprise tools. Learn more at Speaks - Marketing analytics and attribution platform CONTACT: Media Contact Company Name: Data Speaks Contact Person: Zeke Camusio Email: zeke@ Phone: 503-367-7561 Country: United States Website:
Yahoo
2 hours ago
- Yahoo
New Data from Teva Shows Substantial Rates of Undertreated Tardive Dyskinesia in Long-Term Care Settings at Psych Congress Elevate 2025
PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a study of treatment patterns among patients with tardive dyskinesia (TD) residing in long-term care (LTC) facilities, highlighting a critical gap in TD diagnosis and treatment. "These results underscore the need for accurate diagnosis and timely treatment initiation for patients living with tardive dyskinesia in a long-term care setting,' said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. "At Teva, we are committed to better understand and raise awareness of the gaps in TD care in all patients.' Key results from the study revealed: Of the residents being treated with antipsychotic drugs (APDs), 5.6% had a diagnosis of extrapyramidal syndrome (EPS), – a broad term used to describe any drug-induced movement disorder with no wide-treating therapeutic option – while 1.1% had a specific diagnosis of TD. The most common comorbidities observed in residents on APDs at risk for TD included dementia, chronic pulmonary disease and congestive heart failure. Moderate or severe liver disease was observed in <1% of residents on APDs. Less than half of patients diagnosed with TD residing in LTC settings received the standard of care treatment recommended by the American Psychiatric Association – a vesicular monoamine transporter 2 inhibitor (VMAT2i). The majority were treated with a non-FDA approved treatment, primarily benztropine, and a quarter were not treated at all. 'Tardive dyskinesia remains a challenge to identify and is often mistaken for other conditions resulting in undertreatment or inappropriate treatment, often because of confusion about the symptoms a patient is having and also around appropriate treatment options,' said Amita Patel, MD, CMD, MHA, CPE. 'These findings underscore the need to better understand and address the gaps in care that exist for residents in long-term care. Ultimately, it's imperative that residents work with their healthcare providers to seek appropriate diagnoses and learn about potential treatments for TD.' This study retrospectively analyzed a database of residents at risk for TD – those on an APD for ≥30 days and/or metoclopramide (Reglan®) for >12 weeks. Of the ~700,000 residents on an APD and ~35,000 on Reglan®, the most common underlying psychiatric diagnosis was a mood disorder (68% and 54%, respectively). These findings illustrate that a substantial portion of individuals with TD residing in LTC facilities are at risk of not receiving an appropriate diagnosis or proper standard of care, highlighting the need for more intensive evaluation of residents in LTC for TD, to improve the accuracy of diagnoses and the provision of proper treatments. Full results from the study were presented at Psych Congress Elevate on May 30, 2025, with additional data expected later this year. Use of Trademarks Reglan® is a registered trademark of UCB. About Tardive Dyskinesia (TD)Tardive dyskinesia (TD) is a highly debilitating, chronic movement disorder that affects one in four people who take certain mental health treatments and is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact individuals.1,2,3 About TevaTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients' needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit Teva Cautionary Note Regarding Forward Looking StatementsThis Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned 'Risk Factors and 'Forward Looking Statements.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. References Warikoo N, Schwartz T, Citrome L. Tardive dyskinesia. In: Schwartz TL, Megna J, Topel ME, eds. Antipsychotic Drugs. Hauppauge, NY: Nova Science Publishers. 2013:235-258. Waln O, Jankovic J. An Update on Tardive Dyskinesia: From Phenomenology to Treatment. Tremor Other Hyperkinet Mov. 2013;3:1-11. Tardive dyskinesia. National Alliance on Mental Illness website. Accessed May 4, 2023. Teva Media Inquiries:TevaCommunicationsNorthAmerica@ Investor Relations Inquires:TevaIR@ in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Teva Presents Latest Schizophrenia Portfolio Data Including Real-World Outcomes with UZEDY® (risperidone) Showing Lower Rates of and Longer Time to Relapse Compared to Oral Treatment Options and New Phase 3 SOLARIS Data Showing No Incidence of PDSS with TEV-'749 (olanzapine) to Date
Real-world claims studies evaluating UZEDY® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-'749 after more than 3,400 subcutaneous injections in study participants to date As a leader in neuroscience, Teva is committed to researching and developing long-acting treatment options that help address unmet needs for individuals living with schizophrenia PARSIPPANY, N.J. and TEL AVIV, Israel, May 30, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of real-world clinical outcomes, treatment patterns and healthcare resource utilization (HCRU) data evaluating UZEDY® (risperidone), an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, versus second-generation daily oral options. In the studies, patients receiving UZEDY had lower rates of and longer time to relapse as well as better treatment adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits, shorter hospital length of stay and lower all-cause HCRU. Additionally, Phase 3 SOLARIS data show no incidence of post-injection delirium/sedation syndrome (PDSS) to date in participants taking TEV-'749, a once-monthly, long-acting injectable (LAI) subcutaneous formulation of olanzapine. The systemic safety profile was consistent with approved olanzapine options. The data were presented at the 2025 Psych Congress Elevate Annual Meeting, taking place from May 28-31, 2025, in Las Vegas, Nevada. 'People living with schizophrenia and their caregivers face a number of significant daily challenges, including barriers to optimal treatment. For those who struggle adhering to a daily oral regimen, UZEDY may be an appropriate option to help prevent relapse, reduce hospital visits and lower overall costs to the healthcare system,' said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. 'With TEV-'749, our latest data demonstrate its potential to fill a critical gap in the current schizophrenia treatment landscape as a long-acting formulation of olanzapine that may effectively address the risk of PDSS.' UZEDY Data Two retrospective cohort studies evaluating UZEDY explored claims data comparing outcomes in adults living with schizophrenia who were continuously enrolled in Medicaid, Medicare or commercial health plans.1 Patients were followed for two years before and six months after starting UZEDY (n=720), second generation oral antipsychotics (SGOA) (n=720) or oral risperidone (n=720).1 Key findings are summarized below: Real-World Clinical Outcomes UZEDY was associated with a lower relapse rate (9.0% vs. 15.4% for SGOAs and 16.8% for oral risperidone) and a longer mean time to relapse (94 days vs. 61 days for SGOAs and 69 days for oral risperidone).1 Real-World Treatment Patterns and HCRU (UZEDY versus SGOAs) A higher percentage of individuals on UZEDY demonstrated good adherence (medication possession ratio ≥0.8; 71.3% vs. 52.8% for SGOAs) and treatment persistence by staying on treatment longer (120 days vs. 96 days for SGOAs).1 UZEDY was also associated with shorter hospital stays (8 days vs. 16 days for SGOAs) and lower proportions of patients requiring inpatient (15% vs. 29.6% for SGOAs) or ED visits (22.5% vs. 31.7% for SGOAs). Additionally, patients on UZEDY had fewer outpatient visits (6.3 vs. 8.6 per person/year for SGOAs).1 Mean all-cause HCRU costs were lower among adult patients on UZEDY ($18,796 vs. $26,376 for SGOAs).1 TEV-'749 Data In Period 1 of the SOLARIS trial, TEV-'749 met its primary efficacy endpoint across all three dosing groups (318mg, 425mg, 531mg), with statistically significant mean differences in the change in Positive and Negative Syndrome Scale (PANSS) total scores from baseline to week 8 (-9.75 points, -11.27 points, and -9.76 points, respectively) versus placebo.1 Additional safety results from Period 1 (3,487 active injections) show no suspected or confirmed PDSS events reported as of March 2025.1 The systemic safety profile of TEV-'749 was consistent with other approved formulations of olanzapine, with no new safety signals identified.1 With nearly 30 years of clinical and real-world use, olanzapine is one of the most commonly prescribed SGOAs for schizophrenia around the world. Its efficacy and safety profiles are well established. Below is the full set of schizophrenia data presented by Teva at Psych Congress Elevate 2025: UZEDY (risperidone): (De novo) Real-World Clinical Outcomes Among Patients Receiving the Long-Acting Injectable Antipsychotic TV-46000 Versus Second-Generation Oral Antipsychotics (De novo) Treatment Patterns and Healthcare Resource Utilization Among Patients Receiving the Long-Acting Injectable Antipsychotic TV-46000 Versus Second-Generation Oral Antipsychotics TEV-'749 (olanzapine): (De novo) Olanzapine for Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use Is Designed for Sustained Efficacy and to Eliminate the Risk of Post-injection Delirium/Sedation Syndrome: In Vitro and Clinical Data (Encore) Efficacy of Olanzapine Extended-Release Injectable Suspension (TV-44749) for Subcutaneous Use Demonstrated in Patients With Schizophrenia: Results From a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial (SOLARIS) (De novo) Long-acting Injectable Treatments for Schizophrenia: Differences in Attitudes and Preferences Among Healthcare Professionals and Patients From the SOLARIS Trial Experiences Study Schizophrenia Treatment Landscape: (De novo) Clinician Perspectives on the Efficacy and Safety/Tolerability of Olanzapine Compared With Other Antipsychotics: Results From the SONAR (Survey on Olanzapine Needs and Attitudes Research) Study (De novo) Real-World Treatment Patterns of Patients With Schizophrenia Using Oral Olanzapine and the Associated Impact of Non-adherence on Healthcare Resource Utilization (De novo) Use Of Machine Learning to Identify Variations in Clinical Characteristics, Healthcare Resource Utilization, and Treatment Adherence Among Patients With Schizophrenia Initiating Oral Olanzapine Treatment (De novo) Enabling Conversations About Long-Acting Injectable Antipsychotics Among HCPs, Patients, and Caregivers With the Long-Acting Injectables: Conversations and Resources for Education (LAI-CARE) (De novo) Perspectives of Psychiatrists and Psychiatric Nonphysicians on Treating Schizophrenia With Long-Acting Injectable Antipsychotics: Subgroup Analysis From Multinational ADVANCE Study TEV-'749 is an investigational once-monthly subcutaneous LAI of the second-generation antipsychotic olanzapine and is not approved by any regulatory authority for any use, and its safety and efficacy are not established. The long-term safety of TEV-'749 and incidence of PDSS are being evaluated in the SOLARIS open-label study (Period 2). TEV-'749 and UZEDY utilize SteadyTeq™, a copolymer technology proprietary to MedinCell that provides a controlled steady release of olanzapine and risperidone, respectively. UZEDY was approved in the U.S. for the treatment of schizophrenia in adults in 2023.1 About UZEDYUZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for the treatment of schizophrenia in adults. In clinical trials, UZEDY significantly reduced the risk of schizophrenia relapse.1,2 UZEDY administers risperidone through copolymer technology under license from MedinCell that allows for rapid absorption and sustained release after subcutaneous injection. UZEDY is the only long-acting, subcutaneous formulation of risperidone available in both one- and two-month dosing intervals.2 For full prescribing information, visit About Subcutaneous OLAnzapine Extended-Release Injection Study (SOLARIS)SOLARIS is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of olanzapine extended-release injectable suspension for subcutaneous use as a treatment in patients (ages 18-65 years) with schizophrenia.1 For period one of the study (first 8 weeks), 675 patients were randomized to receive a subcutaneous injection of once-monthly TEV-'749 (low, medium or high dose) or placebo in a 1:1:1:1 ratio.1 For period two, which will last for up to 48 weeks, patients who completed period one are randomized and equally allocated to one of the three TEV-'749 treatment groups.1 The end-of-treatment and follow-up visits will be at 4 and 8 weeks after administration of the last treatment dose, respectively.1 The primary objective of the Phase 3 SOLARIS study was to evaluate the efficacy of TEV-'749 in adult patients with schizophrenia.1 A key secondary objective was to further evaluate the efficacy of TEV-'749 based on additional parameters in adult patients with schizophrenia.1 A secondary objective that is still ongoing through period two of the study is to evaluate the safety and tolerability of TEV-'749 in adult patients with schizophrenia.1 About SchizophreniaSchizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts.3 Patients experience an array of symptoms, which may include delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability.3,4,5 Approximately 1% of the world's population will develop schizophrenia in their lifetime, and 3.5 million people in the U.S. are currently diagnosed with the condition.4,5 Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 20s for men, and the late 20s to early 30s for women.5 The long-term course of schizophrenia is marked by episodes of partial or full remission broken by relapses that often occur in the context of psychiatric emergency and require hospitalization.5 Approximately 80% of patients experience multiple relapses over the first five years of treatment, and each relapse carries a biological risk of loss of function, treatment refractoriness, and changes in brain morphology.6,7,8 Patients are often unaware of their illness and its consequences, contributing to treatment nonadherence, high discontinuation rates, and ultimately, significant direct and indirect healthcare costs from subsequent relapses and hospitalizations.3,4,5,6,7,8 INDICATION AND USAGE UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for the treatment of schizophrenia in adults. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. UZEDY is not approved for use in patients with dementia-related psychosis and has not been studied in this patient population. See below for additional Important Safety Information. IMPORTANT SAFETY INFORMATION CONTINUED CONTRAINDICATIONS: UZEDY is contraindicated in patients with a known hypersensitivity to risperidone, its metabolite, paliperidone, or to any of its components. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone or paliperidone. WARNINGS AND PRECAUTIONS Cerebrovascular Adverse Reactions: In trials of elderly patients with dementia-related psychosis, there was a significantly higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, in patients treated with oral risperidone compared to placebo. UZEDY is not approved for use in patients with dementia-related psychosis. Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status including delirium, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis), and acute renal failure. If NMS is suspected, immediately discontinue UZEDY and provide symptomatic treatment and monitoring. Tardive Dyskinesia (TD): TD, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause TD is unknown. The risk of developing TD and the likelihood that it will become irreversible are believed to increase with the duration of treatment and the cumulative dose. The syndrome can develop, after relatively brief treatment periods, even at low doses. It may also occur after discontinuation. TD may remit, partially or completely, if antipsychotic treatment is discontinued. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome, possibly masking the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. If signs and symptoms of TD appear in a patient treated with UZEDY, drug discontinuation should be considered. However, some patients may require treatment with UZEDY despite the presence of the syndrome. In patients who do require chronic treatment, use the lowest dose and the shortest duration of treatment producing a satisfactory clinical response. Periodically reassess the need for continued treatment. Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile. Hyperglycemia and diabetes mellitus (DM): in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, have been reported in patients treated with atypical antipsychotics, including risperidone. Patients with an established diagnosis of DM who are started on atypical antipsychotics, including UZEDY, should be monitored regularly for worsening of glucose control. Patients with risk factors for DM (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics, including UZEDY, should undergo fasting blood glucose (FBG) testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics, including UZEDY, should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics, including UZEDY, should undergo FBG testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic, including risperidone, was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of risperidone. Dyslipidemia has been observed in patients treated with atypical antipsychotics. Weight gain has been observed with atypical antipsychotic use. Monitoring weight is recommended. Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, risperidone elevates prolactin levels and the elevation persists during chronic administration. Risperidone is associated with higher levels of prolactin elevation than other antipsychotic agents. Orthostatic Hypotension and Syncope: UZEDY may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope. UZEDY should be used with particular caution in patients with known cardiovascular disease, cerebrovascular disease, and conditions which would predispose patients to hypotension and in the elderly and patients with renal or hepatic impairment. Monitoring of orthostatic vital signs should be considered in all such patients, and a dose reduction should be considered if hypotension occurs. Clinically significant hypotension has been observed with concomitant use of oral risperidone and antihypertensive medication. Falls: Antipsychotics, including UZEDY, may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other fall-related injuries. Somnolence, postural hypotension, motor and sensory instability have been reported with the use of risperidone. For patients, particularly the elderly, with diseases, conditions, or medications that could exacerbate these effects, assess the risk of falls when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy. Leukopenia, Neutropenia, and Agranulocytosis have been reported with antipsychotic agents, including risperidone. In patients with a pre-existing history of a clinically significant low white blood cell count (WBC) or absolute neutrophil count (ANC) or a history of drug-induced leukopenia or neutropenia, perform a complete blood count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of UZEDY at the first sign of a clinically significant decline in WBC in the absence of other causative factors. Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue UZEDY in patients with ANC < 1000/mm3) and follow their WBC until recovery. Potential for Cognitive and Motor Impairment: UZEDY, like other antipsychotics, may cause somnolence and has the potential to impair judgement, thinking, and motor skills. Somnolence was a commonly reported adverse reaction associated with oral risperidone treatment. Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that treatment with UZEDY does not affect them adversely. Seizures: During premarketing studies of oral risperidone in adult patients with schizophrenia, seizures occurred in 0.3% of patients (9 out of 2,607 patients), two in association with hyponatremia. Use UZEDY cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold. Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Antipsychotic drugs, including UZEDY, should be used cautiously in patients at risk for aspiration. Priapism has been reported during postmarketing surveillance for other risperidone products. A case of priapism was reported in premarket studies of UZEDY. Severe priapism may require surgical intervention. Body temperature regulation. Disruption of the body's ability to reduce core body temperature has been attributed to antipsychotic agents. Both hyperthermia and hypothermia have been reported in association with oral risperidone use. Strenuous exercise, exposure to extreme heat, dehydration, and anticholinergic medications may contribute to an elevation in core body temperature; use UZEDY with caution in patients who experience these conditions. ADVERSE REACTIONSThe most common adverse reactions with risperidone (≥5% and greater than placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis, and pharyngolaryngeal pain. The most common injection site reactions with UZEDY (≥5% and greater than placebo) were pruritus and nodule. DRUG INTERACTIONS Carbamazepine and other strong CYP3A4 inducers decrease plasma concentrations of risperidone. Fluoxetine, paroxetine, and other strong CYP2D6 inhibitors increase risperidone plasma concentration. Due to additive pharmacologic effects, the concomitant use of centrally-acting drugs, including alcohol, may increase nervous system disorders. UZEDY may enhance the hypotensive effects of other therapeutic agents with this potential. UZEDY may antagonize the pharmacologic effects of dopamine agonists. Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS) USE IN SPECIFIC POPULATIONS Pregnancy: May cause EPS and/or withdrawal symptoms in neonates with third trimester exposure. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including UZEDY, during pregnancy. Healthcare providers are encouraged to register patients by contacting the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or online at Lactation: Infants exposed to risperidone through breastmilk should be monitored for excess sedation, failure to thrive, jitteriness, and EPS. Fertility: UZEDY may cause a reversible reduction in fertility in females. Pediatric Use: Safety and effectiveness of UZEDY have not been established in pediatric patients. Renal or Hepatic Impairment: Carefully titrate on oral risperidone up to at least 2 mg daily before initiating treatment with UZEDY. Patients with Parkinson's disease or dementia with Lewy bodies can experience increased sensitivity to UZEDY. Manifestations and features are consistent with NMS. Please see the full Prescribing Information for UZEDY, including Boxed WARNING. About TevaTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader, one that operates across the full spectrum of innovation to reliably deliver medicines to patients worldwide. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company's global network of capabilities enables its 37,000 employees across 57 markets to advance health by developing medicines for the future while championing the production of generics and biologics. We are dedicated to addressing patients' needs, now and in the future. Moving forward together with science that treats, inspired by the people we serve. To learn more about how Teva is all in for better health, visit Cautionary Note Regarding Forward-Looking StatementsThis Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop TEV-'749 (olanzapine LAI) in adult patients diagnosed with schizophrenia; our ability to successfully develop and commercialize UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in our Quarterly Report on Form 10-Q for the first quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the sections captioned 'Risk Factors and 'Forward Looking Statements.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. Data on file. Parsippany, NJ: Teva Neuroscience, Inc. UZEDY (risperidone) extended-release injectable suspension, for subcutaneous injection Current Prescribing Information. Parsippany, NJ. Teva Neuroscience, Inc. Substance Abuse and Mental Health Services Administration. Schizophrenia. Velligan DI, Rao S. The Epidemiology and Global Burden of Schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. Wander C. (2020). Schizophrenia: Opportunities to Improve Outcomes and Reduce Economic Burden Through Managed Care. The Am J Manag Care. 26(3 Suppl), S62–S68. Emsley, R., & Kilian, S. (2018). Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric Dis. Treat., 14, 205–223. Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13, 50. Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. The Am J Psychiatry, 170(6), 609–615. Teva Media Inquiries:TevaCommunicationsNorthAmerica@ Investor Relations InquiresTevaIR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
